These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9068790)

  • 1. Intrabodies: turning the humoral immune system outside in for intracellular immunization.
    Marasco WA
    Gene Ther; 1997 Jan; 4(1):11-5. PubMed ID: 9068790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular antibodies (intrabodies) and their therapeutic potential.
    Lo AS; Zhu Q; Marasco WA
    Handb Exp Pharmacol; 2008; (181):343-73. PubMed ID: 18071953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrabodies as drug discovery tools and therapeutics.
    Stocks M
    Curr Opin Chem Biol; 2005 Aug; 9(4):359-65. PubMed ID: 15979379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrabody applications in neurological disorders: progress and future prospects.
    Miller TW; Messer A
    Mol Ther; 2005 Sep; 12(3):394-401. PubMed ID: 15964243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation.
    Visintin M; Quondam M; Cattaneo A
    Methods; 2004 Oct; 34(2):200-14. PubMed ID: 15312673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
    Heng BC; Cao T
    Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent progress in biomolecular engineering.
    Ryu DD; Nam DH
    Biotechnol Prog; 2000; 16(1):2-16. PubMed ID: 10662483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retroviral vectors for gene therapy of AIDS and cancer.
    Chang LJ; He J
    Curr Opin Mol Ther; 2001 Oct; 3(5):468-75. PubMed ID: 11699891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic gene therapy. Present situation and future perspective.
    Gottschalk U; Chan S
    Arzneimittelforschung; 1998 Nov; 48(11):1111-20. PubMed ID: 9850435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules.
    Lobato MN; Rabbitts TH
    Curr Mol Med; 2004 Aug; 4(5):519-28. PubMed ID: 15267223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered antibodies take center stage.
    Huston JS; George AJ
    Hum Antibodies; 2001; 10(3-4):127-42. PubMed ID: 11847424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoplasmic expression and specific binding of the VH/VL single domain intrabodies in transfected NIH3T3 cells.
    Sawahata R; Sato M; Kitani H
    Exp Mol Pathol; 2009 Feb; 86(1):51-6. PubMed ID: 19094983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended half-life upon binding of destabilized intrabodies allows specific detection of antigen in mammalian cells.
    Sibler AP; Courtête J; Muller CD; Zeder-Lutz G; Weiss E
    FEBS J; 2005 Jun; 272(11):2878-91. PubMed ID: 15943819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME; Morea V; Consalvi V; Chiaraluce R; Desiderio A; Benvenuto E; Donini M
    Mol Immunol; 2008 May; 45(9):2474-85. PubMed ID: 18313757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of oculopharyngeal muscular dystrophy by muscular expression of Llama single-chain intrabodies in vivo.
    Chartier A; Raz V; Sterrenburg E; Verrips CT; van der Maarel SM; Simonelig M
    Hum Mol Genet; 2009 May; 18(10):1849-59. PubMed ID: 19258344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
    Sanz L; Blanco B; Alvarez-Vallina L
    Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Gene therapy and its applications].
    Austin-Ward ED; Villaseca C
    Rev Med Chil; 1998 Jul; 126(7):838-45. PubMed ID: 9830778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineered affinity proteins for tumour-targeting applications.
    Friedman M; Ståhl S
    Biotechnol Appl Biochem; 2009 May; 53(Pt 1):1-29. PubMed ID: 19341363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The potential of intracellular antibodies for therapeutic targeting of protein-misfolding diseases.
    Cardinale A; Biocca S
    Trends Mol Med; 2008 Sep; 14(9):373-80. PubMed ID: 18693139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of functional scFv intrabodies for triggering anti-tumor immunity.
    Bonnin E; Gruel N; Moutel S; Mantegazza AR; Barrio MM; Mordoh J; Teillaud JL
    Methods; 2004 Oct; 34(2):225-32. PubMed ID: 15312675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.